Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours
Journal of Neuroendocrinology · 2023
DOI: 10.1111/jne.13342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2023. Verfasst von Katarina Edfeldt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which amongst other factors may affect patients' health‐related quality of life (HRQoL). Up to four cycles of peptide receptor radionuclide therapy (PRRT) have been shown effective for symptom alleviation and prolonging progression‐free survival. The aim of this study was to assess the patient's perspective regarding changes in their HRQoL during PRRT. HRQoL was assessed using the questionnaires for cancer in general, EORTC QLQ‐C30, and the gastrointestinal NET‐specifically EORTC QLQ‐GINET21. Patients with NET ( n = 204) rated their HRQoL before PRRT cycles one and four. The medical records of patients were reviewed and their HRQoL was compared to a matched reference population ( n = 4910). HRQoL was found to improve during PRRT in aspects of global quality of life; role, social, and emotional functioning, and multiple symptom relief. Potential risk groups for worse HRQoL during PRRT were patients with overweight (BMI >25) who completed four cycles of PRRT and older patients (>65 years old). In conclusion, we found that PRRT improves HRQoL in patients with NETs. The results of this study may be used to improve person‐centred care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Katarina Edfeldt, Espen Thiis-Evensen, Anders Sundin
Zitieren
APA
Edfeldt, K., Hellman, P., Granberg, D., Lagergren, P., Thiis-Evensen, E., Sundin, A., & Andersson, C. (2023). Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13342
Vancouver
Edfeldt K, Hellman P, Granberg D, Lagergren P, Thiis-Evensen E, Sundin A, et al. Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours. Journal of Neuroendocrinology. 2023. doi:10.1111/jne.13342
BibTeX
@article{Edfeldt2023,
author = {Edfeldt, Katarina and Hellman, Per and Granberg, Dan and Lagergren, Pernilla and Thiis-Evensen, Espen and Sundin, Anders and Andersson, Camilla},
title = {Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours},
journal = {Journal of Neuroendocrinology},
year = {2023},
doi = {10.1111/jne.13342}
}
EUVIMED